Europe & Central Asia (IDA & IBRD countries) vs Maldives: Immunization, Hib3
Immunization, Hib3 over time
- Europe & Central Asia (IDA & IBRD countries)
- Maldives
How they compare
Maldives currently reports 99.0% against 93.4% in Europe & Central Asia (IDA & IBRD countries), a difference of 5.6%.
That makes Maldives's figure about 1.1 times Europe & Central Asia (IDA & IBRD countries)'s.
The two have swapped places 1 time across 12 shared years of data; in 2013 it was Europe & Central Asia (IDA & IBRD countries) ahead.
Europe & Central Asia (IDA & IBRD countries) ranks 3rd and Maldives ranks 1st of 43 groups.
Maldives has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe & Central Asia (IDA & IBRD countries) | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 64.8% | 92.6% | 27.7% | Maldives |
| 2020s | 83.7% | 97.6% | 13.9% | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Europe & Central Asia (IDA & IBRD countries) or Maldives?
- Maldives, at 99.0% against 93.4% in Europe & Central Asia (IDA & IBRD countries) as of 2024.
- What is the difference in immunization, hib3 between Europe & Central Asia (IDA & IBRD countries) and Maldives?
- 5.6%, with Maldives ahead.
- How many years of comparable data are there for Europe & Central Asia (IDA & IBRD countries) and Maldives?
- 12 years are reported by both, from 2013 to 2024.
- How do Europe & Central Asia (IDA & IBRD countries) and Maldives rank globally for immunization, hib3?
- Europe & Central Asia (IDA & IBRD countries) ranks 3rd and Maldives ranks 1st of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.